Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL)

Leukemia Research

Volumn 37, Issue 11, 2013, Pages 1420-1428

  Mazan Mamczarz, Krystyna ^a   Gartenhaus, Ronald B ^a,b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

DLBCL; Lymphoma; Microrna

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MICRORNA; MICRORNA 155; MICRORNA 17 92; MICRORNA 21; MICRORNA 34; PREDNISOLONE; RITUXIMAB; TUMOR MARKER; UNCLASSIFIED DRUG; VINCRISTINE;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER MODEL; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; DOWN REGULATION; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; LARGE CELL LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; UPREGULATION;

DLBCL; LYMPHOMA; MICRORNA;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICRORNAS;

EID: 84886769479     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.08.020     Document Type: Review

References (128)

1. Denli A.M., Tops B.B., Plasterk R.H., Ketting R.F., Hannon G.J. Processing of primary microRNAs by the microprocessor complex. Nature 2004, 432:231-235.
2. Chendrimada T.P., Gregory R.I., Kumaraswamy E., Norman J., Cooch N., Nishikura K., et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005, 436:740-744.
3. Lee Y., Hur I., Park S.Y., Kim Y.K., Suh M.R., Kim V.N. The role of PACT in the RNA silencing pathway. EMBO J 2006, 25:522-532.
4. Robb G.B., Rana T.M. RNA helicase A interacts with RISC in human cells and functions in RISC loading. Mol Cell 2007, 26:523-537.
5. Kim V.N., Han J., Siomi M.C. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009, 10:126-139.
6. Newman M.A., Hammond S.M. Emerging paradigms of regulated microRNA processing. Genes Dev 2010, 24:1086-1092.
7. Zhou H., Huang X., Cui H., Luo X., Tang Y., Chen S., et al. miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells. Blood 2010, 116:5885-5894.
8. Yang J.S., Phillips M.D., Betel D., Mu P., Ventura A., Siepel A.C., et al. Widespread regulatory activity of vertebrate microRNA* species. RNA 2011, 17:312-326.
9. Jiang L., Lin C., Song L., Wu J., Chen B., Ying Z., et al. MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-(B/I(Bα negative feedback loop. J Clin Invest 2012, 122:33-47.
10. Wu J., Lu C., Diao N., Zhang S., Wang S., Wang F., et al. Analysis of microRNA expression profiling identifies miR-155 and miR-155* as potential diagnostic markers for active tuberculosis: a preliminary study. Hum Immunol 2012, 73:31-37.
11. Chang K.W., Kao S.Y., Wu Y.H., Tsai M.M., Tu H.F., Liu C.J., et al. Passenger strand miRNA miR-31* regulates the phenotypes of oral cancer cells by targeting RhoA. Oral Oncol 2013, 49:27-33.
12. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
13. Fabian M.R., Sonenberg N., Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010, 79:351-379.
14. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
15. Wightman B., Ha I., Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75:855-862.
16. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
17. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
18. Krek A., Grün D., Poy M.N., Wolf R., Rosenberg L., Epstein E.J., et al. Combinatorial microRNA target predictions. Nat Genet 2005, 37:495-500.
19. Baek D., Villén J., Shin C., Camargo F.D., Gygi S.P., Bartel D.P. The impact of microRNAs on protein output. Nature 2008, 455:64-71.
20. Selbach M., Schwanhäusser B., Thierfelder N., Fang Z., Khanin R., Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58-63.
21. Du L., Schageman J.J., Subauste M.C., Saber B., Hammond S.M., Prudkin L., et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 2009, 7:1234-1243.
22. Marasa B.S., Srikantan S., Masuda K., Abdelmohsen K., Kuwano Y., Yang X., et al. Increased MKK4 abundance with replicative senescence is linked to the joint reduction of multiple microRNAs. Sci Signal 2009, 2:ra69.
23. Wu S., Huang S., Ding J., Zhao Y., Liang L., Liu T., et al. Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region. Oncogene 2010, 29:2302-2308.
24. Sirotkin A.V., Lauková M., Ovcharenko D., Brenaut P., Mlyncek M. Identification of microRNAs controlling human ovarian cell proliferation and apoptosis. J Cell Physiol 2010, 223:49-56.
25. Serva A., Claas C., Starkuviene V.A. Potential of microRNAs for high-content screening. J Nucleic Acids 2011, 2011:870903.
26. Meltzer P.S. Cancer genomics: small RNAs with big impacts. Nature 2005, 435:745-746.
27. Zhang B., Pan X., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007, 302:1-12.
28. Thomson J.M., Newman M., Parker J.S., Morin-Kensicki E.M., Wright T., Hammond S.M. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 2006, 20:2202-2207.
29. Basso K., Sumazin P., Morozov P., Schneider C., Maute R.L., Kitagawa Y., et al. Identification of the human mature B cell miRNome. Immunity 2009, 30:744-752.
30. Malumbres R., Sarosiek K.A., Cubedo E., Ruiz J.W., Jiang X., Gascoyne R.D., et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009, 113:3754-3764.
31. Fu J., Tang W., Du P., Wang G., Chen W., Li J., et al. Identifying microRNA-mRNA regulatory network in colorectal cancer by a combination of expression profile and bioinformatics analysis. BMC Syst Biol 2012, 6:68.
32. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101:2999-3004.
33. Rossi S., Sevignani C., Nnadi S.C., Siracusa L.D., Calin G.A. Cancer-associated genomic regions (CAGRs) and noncoding RNAs: bioinformatics and therapeutic implications. Mamm Genome 2008, 19:526-540.
34. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., et al. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
35. Garzon R., Fabbri M., Cimmino A., Calin G.A., Croce C.M. MicroRNA expression and function in cancer. Trends Mol Med 2006, 12:580-587.
36. Koturbash I., Zemp F.J., Pogribny I., Kovalchuk O. Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis. Mutat Res 2011, 722:94-105.
37. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070.
38. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
39. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
40. Corsini L.R., Bronte G., Terrasi M., Amodeo V., Fanale D., Fiorentino E., et al. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets 2012, 16:S103-S109.
41. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353:1793-1801.
42. Lawrie C.H., Soneji S., Marafioti T., Cooper C.D., Palazzo S., Paterson J.C., et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 2007, 121:1156-1161.
43. Lawrie C.H., Saunders N.J., Soneji S., Palazzo S., Dunlop H.M., Cooper C.D., et al. MicroRNA expression in lymphocyte development and malignancy. Leukemia 2008, 22:1440-1446.
44. Lawrie C.H., Chi J., Taylor S., Tramonti D., Ballabio E., Palazzo S., et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med 2009, 13:1248-1260.
45. Garzon R., Volinia S., Liu C.G., Fernandez-Cymering C., Palumbo T., Pichiorri F., et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111:3183-3189.
46. Marcucci G., Radmacher M.D., Maharry K., Mrózek K., Ruppert A.S., Paschka P., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1919-1928.
47. Babar I.A., Cheng C.J., Booth C.J., Liang X., Weidhaas J.B., Saltzman W.M., et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A 2012, 109:E1695-E1704.
48. Kovalchuk O., Filkowski J., Meservy J., Ilnytskyy Y., Tryndyak V.P., Chekhun V.F., et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008, 7:2152-2159.
49. Hummel R., Hussey D.J., Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010, 46:298-311.
50. Alencar A.J., Malumbres R., Kozloski G.A., Advani R., Talreja N., Chinichian S., et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res 2011, 17:4125-4135.
51. Montes-Moreno S., Martinez N., Sanchez-Espiridión B., Díaz Uriarte R., Rodriguez M.E., Saez A., et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood 2011, 118:1034-1040.
52. Campo E., Swerdlow S.H., Harris N.L., Pileri S., Stein H., Jaffe E.S. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011, 117:5019-5032.
53. Lossos I.S., Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:995-1007.
54. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
55. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
56. Wright G., Tan B., Rosenwald A., Hurt E.H., Wiestner A., Staudt L.M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003, 100:9991-9996.
57. Wilson W.H., Dunleavy K., Pittaluga S., Hegde U., Grant N., Steinberg S.M., et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008, 26:2717-2724.
58. Habermann T.M., Weller E.A., Morrison V.A., Gascoyne R.D., Cassileth P.A., Cohn J.B., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121-3127.
59. Pfreundschuh M., Trümper L., Osterborg A., Pettengell R., Trneny M., Imrie K., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391.
60. Bai H., Wei J., Deng C., Yang X., Wang C., Xu R. MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen. Int J Hematol 2013, 97:223-231.
61. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
62. Feugier P., Van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Fermé C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-4126.
63. Sehn L.H., Donaldson J., Chhanabhai M., Fitzgerald C., Gill K., Klasa R., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23:5027-5033.
64. Sehn L.H., Berry B., Chhanabhai M., Fitzgerald C., Gill K., Hoskins P., et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109:1857-1861.
65. Zhang J., Jima D.D., Jacobs C., Fischer R., Gottwein E., Huang G., et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009, 113:4586-4594.
66. Jima D.D., Zhang J., Jacobs C., Richards K.L., Dunphy C.H., Choi W.W., et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 2010, 116:e118-e127.
67. Di Lisio L., Martinez N., Montes-Moreno S., Piris-Villaespesa M., Sanchez-Beato M., Piris M.A. The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood 2012, 120:1782-1790.
68. Roehle A., Hoefig K.P., Repsilber D., Thorns C., Ziepert M., Wesche K.O., et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol 2008, 142:732-744.
69. Ota A., Tagawa H., Karnan S., Tsuzuki S., Karpas A., Kira S., et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004, 64:3087-3095.
70. Xiao C., Srinivasan L., Calado D.P., Patterson H.C., Zhang B., Wang J., et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008, 9:405-414.
71. Tagawa H., Karube K., Tsuzuki S., Ohshima K., Seto M. Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. Cancer Sci 2007, 98:1482-1490.
72. Ventura A., Young A.G., Winslow M.M., Lintault L., Meissner A., Erkeland S.J., et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008, 132:875-876.
73. Mu P., Han Y.C., Betel D., Yao E., Squatrito M., Ogrodowski P., et al. Genetic dissection of the miR-17-92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 2009, 23:2806-2811.
74. Olive V., Bennett M.J., Walker J.C., Ma C., Jiang I., Cordon-Cardo C., et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 2009, 23:2839-2849.
75. Lenz G., Wright G.W., Emre N.C., Kohlhammer H., Dave S.S., Davis R.E., et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008, 105:13520-13525.
76. Fassina A., Marino F., Siri M., Zambello R., Ventura L., Fassan M., et al. The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. Lab Invest 2012, 92:1574-1582.
77. Inomata M., Tagawa H., Guo Y.M., Kameoka Y., Takahashi N., Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 2009, 113:396-402.
78. Rodriguez A., Vigorito E., Clare S., Warren M.V., Couttet P., Soond D.R., et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007, 316:608-611.
79. Thai T.H., Calado D.P., Casola S., Ansel K.M., Xiao C., Xue Y., et al. Regulation of the germinal center response by microRNA-155. Science 2007, 316:604-608.
80. Li J., Wan Y., Ji Q., Fang Y., Wu Y. The role of microRNAs in B-cell development and function. Cell Mol Immunol 2013, 10:107-112.
81. Kluiver J., Poppema S., de Jong D., Blokzijl T., Harms G., Jacobs S., et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 2005, 207:243-249.
82. Eis P.S., Tam W., Sun L., Chadburn A., Li Z., Gomez M.F., et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 2005, 102:3627-3632.
83. Zhong H., Xu L., Zhong J.H., Xiao F., Liu Q., Huang H.H., et al. Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma. Exp Ther Med 2012, 3:763-770.
84. Costinean S., Sandhu S.K., Pedersen I.M., Tili E., Trotta R., Perrotti D., et al. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood 2009, 114:1374-1382.
85. Huang X., Shen Y., Liu M., Bi C., Jiang C., Iqbal J., et al. Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma. Am J Pathol 2012, 181:26-33.
86. O'Connell R.M., Chaudhuri A.A., Rao D.S., Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA 2009, 106:7113-7118.
87. Pedersen I.M., Otero D., Kao E., Miletic A.V., Hother C., Ralfkiaer E., et al. Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol Med 2009, 1:288-295.
88. Dorsett Y., McBride K.M., Jankovic M., Gazumyan A., Thai T.H., Robbiani D.F., et al. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity 2008, 28:630-638.
89. Teng G., Hakimpour P., Landgraf P., Rice A., Tuschl T., Casellas R., et al. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 2008, 28:621-629.
90. Basso K., Schneider C., Shen Q., Holmes A.B., Setty M., Leslie C., et al. BCL6 positively regulates AID and germinal center gene expression via repression of miR-155. J Exp Med 2012, 209:2455-2465.
91. Rai D., Karanti S., Jung I., Dahia P.L., Aguiar R.C. Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet 2008, 181:8-15.
92. Ma X. Becker Buscaglia LE, Barker JR, Li Y. MicroRNAs in NF-kappaB signaling. J Mol Cell Biol 2011, 3:159-166.
93. Costinean S., Zanesi N., Pekarsky Y., Tili E., Volinia S., Heerema N., et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006, 103:7024-7029.
94. Zhang Y., Roccaro A.M., Rombaoa C., Flores L., Obad S., Fernandes S.M., et al. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood 2012, 120:1678-1686.
95. Fulci V., Chiaretti S., Goldoni M., Azzalin G., Carucci N., Tavolaro S., et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007, 109:4944-4951.
96. Medina P.P., Nolde M., Slack F.J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467:86-90.
97. Craig V.J., Cogliatti S.B., Imig J., Renner C., Neuenschwander S., Rehrauer H., et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 2011, 117:6227-6236.
98. Craig V.J., Tzankov A., Flori M., Schmid C.A., Bader A.G., Müller A. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia 2012, 26:2421-2424.
99. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010, 17:193-199.
100. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007, 26:745-752.
101. He L., He X., Lim L.P., de Stanchina E., Xuan Z., Liang Y., et al. microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134.
102. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007, 26:731-743.
103. Rao D.S., O'Connell R.M., Chaudhuri A.A., Garcia-Flores Y., Geiger T.L., Baltimore D. MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity 2010, 33:48-59.
104. Hoeller S., Schneider A., Haralambieva E., Dirnhofer S., Tzankov A. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1. Histopathology 2010, 57:73-80.
105. Culpin R.E., Proctor S.J., Angus B., Crosier S., Anderson J.J., Mainou-Fowler T. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. Int J Oncol 2010, 37:367-376.
106. Di Lisio L., Sánchez-Beato M., Gómez-López G., Rodríguez M.E., Montes-Moreno S., Mollejo M., et al. MicroRNA signatures in B-cell lymphomas. Blood Cancer J 2012, 2:e57.
107. Lenze D., Leoncini L., Hummel M., Volinia S., Liu C.G., Amato T., et al. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia 2011, 25:1869-1876.
108. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10:704-714.
109. Wada M., Okamura T., Okada M., Teramura M., Masuda M., Motoji T., et al. Frequent chromosome arm 13q deletion in aggressive non-Hodgkin's lymphoma. Leukemia 1999, 13:792-798.
110. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99:15524-15529.
111. Li C., Kim S.W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C., et al. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood 2009, 113:6681-6690.
112. Mian M., Scandurra M., Chigrinova E., Shen Y., Inghirami G., Greiner T.C., et al. Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. Ann Oncol 2012, 23:729-735.
113. Schneider B., Nagel S., Kaufmann M., Winkelmann S., Bode J., Drexler H.G., et al. T(3;7)(q27;q32) fuses BCL6 to a non-coding region at FRA7H near miR-29. Leukemia 2008, 22:1262-1266.
114. Imig J., Motsch N., Zhu J.Y., Barth S., Okoniewski M., Reineke T., et al. microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res 2011, 39:1880-1893.
115. Kwanhian W., Lenze D., Alles J., Motsch N., Barth S., Döll C., et al. MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma. Cancer Med 2012, 1:141-155.
116. Chim C.S., Wong K.Y., Qi Y., Loong F., Lam W.L., Wong L.G., et al. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 2010, 31:745-750.
117. Chim C.S., Wong K.Y., Leung C.Y., Chung L.P., Hui P.K., Chan S.Y., et al. Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J Cell Mol Med 2011, 15:2760-2767.
118. Wong K.Y., So C.C., Loong F., Chung L.P., Lam W.W., Liang R., et al. Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS ONE 2011, 6:e19027.
119. Wong K.Y., Yim R.L., Kwong Y.L., Leung C.Y., Hui P.K., Cheung F., et al. Epigenetic inactivation of the MIR129-2 in hematological malignancies. J Hematol Oncol 2013, 6:16.
120. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
121. Chang T.C., Yu D., Lee Y.S., Wentzel E.A., Arking D.E., West K.M., et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008, 40:43-50.
122. Robertus J.L., Kluiver J., Weggemans C., Harms G., Reijmers R.M., Swart Y., et al. MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma. Br J Haematol 2010, 149:896-899.
123. Martín-Pérez D., Vargiu P., Montes-Moreno S., León E.A., Rodríguez-Pinilla S.M., Lisio L.D., et al. Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma. Leukemia 2012, 26:180-183.
124. Lim E.L., Marra M.A. MicroRNA dysregulation in B-cell non-Hodgkin lymphoma. Blood Lymphatic Cancer: Targets Ther 2013, 3:25-40.
125. Weiland M., Gao X.H., Zhou L., Mi Q.S. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol 2012, 9:850-859.
126. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:672-675.
127. Fang C., Zhu D.X., Dong H.J., Zhou Z.J., Wang Y.H., Liu L., et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol 2012, 91:553-559.
128. Hedström G., Thunberg U., Berglund M., Simonsson M., Amini R.M., Enblad G. Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL). Int J Hematol 2013, 97:465-471.